CD200 Signaling in Tumor Immunology

CD200 is a membrane-bound immunoglobulin superfamily glycoprotein that regulates myeloid cell activity through interaction with its inhibitory receptor, CD200R. In healthy tissues, this axis maintains immune tolerance and prevents excessive inflammation. In the context of cancer, tumour and stromal cells often overexpress CD200, co-opting its suppressive function to dampen antitumour immunity. Engagement of CD200R on myeloid-derived suppressor cells (MDSCs), macrophages and dendritic cells triggers intracellular inhibitory pathways, leading to reduced antigen presentation, elevated production of anti-inflammatory cytokines and expansion of regulatory cell populations. This immunosuppression facilitates tumour growth, metastasis and therapy resistance across a broad spectrum of malignancies. Recent insights into the structural basis of CD200–CD200R binding have enabled the design of agonists and antagonists, while clinical investigations of CD200 blockade demonstrate potential to restore immune surveillance. As a checkpoint distinct from established co-inhibitory pathways, targeting CD200 signalling offers a complementary strategy to enhance the efficacy of existing immunotherapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

CD200 Signaling in Tumor Immunology publication trend

The graph below shows the total number of articles in cd200 signaling in tumor immunology across all publications each year (not limited to Nature Index journals).

Technical terms

CD200: A cell surface glycoprotein that binds to CD200R and transmits inhibitory signals to myeloid cells.

CD200R: A receptor on myeloid lineage cells which, upon engagement by CD200, initiates intracellular pathways that suppress immune activation.

Immune checkpoint: A regulatory pathway in the immune system that either stimulates or inhibits immune responses; tumour cells exploit inhibitory checkpoints to evade detection.

Tumour microenvironment (TME): The complex milieu of cells, extracellular matrix and signalling molecules surrounding a tumour, which influences cancer progression and immune response.

Myeloid-derived suppressor cells (MDSCs): A heterogeneous population of immature myeloid cells that inhibit T cell activity and promote tumour immune evasion.

References

1. CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival. Cancer Immunology, Immunotherapy (2024).
2. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200. International Journal of Molecular Sciences (2023).
3. CD200:CD200R Interactions and Their Importance in Immunoregulation. International Journal of Molecular Sciences (2021).
4. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. Journal for ImmunoTherapy of Cancer (2019).
5. Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution. Structure (2013).